IP Library Granted Patent US 7,176,304
Granted Patent B2
US 7,176,304 · App. 10/844,076 · Granted Feb 13, 2007

RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,176,304
App. No.
10/844,076
Granted
Feb 13, 2007
Kind
B2
Abstract

The present invention concerns methods and reagents useful in modulating vascular endothelial growth factor (VEGF, VEGF-A, VEGF-B, VEGF-C, VEGF-D) and/or vascular endothelial growth factor receptor (e.g., VEGFR1, VEGFR2 and/or VEGFr3) gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against VEGF and/or VEGFr gene expression and/or activity. The small nucleic acid molecules are useful in the diagnosis and treatment of cancer, proliferative diseases, and any other disease or condition that responds to modulation of VEGF and/or VEGFr expression or activity.

Claims (5)

1. A chemically synthesized double stranded short interfering nucleic acid (siNA) molecule that directs cleavage of a vascular endothelial growth factor receptor 1 (VEGER1) RNA via RNA interference (RNAi) wherein:

a. each strand of said siNA molecule is about 21 nucleotides in length;

b. one strand of said siNA molecule comprises a nucleotide sequence having sufficient complementarity to said VEGFR1 RNA for the siNA molecule to direct cleavage of the VEGFR1 RNA via RNA interference; and

c. said siNA comprises SEQ ID NO: 2185 and SEQ ID NO: 2188.

2. A composition comprising the siNA of claim 1 and a pharmaceutically acceptable carrier or diluent.